Fresenius Medical Care (NYSE:FMS) Upgraded at StockNews.com

StockNews.com upgraded shares of Fresenius Medical Care (NYSE:FMS) from a hold rating to a strong-buy rating in a research report released on Wednesday.

A number of other equities research analysts also recently commented on the stock. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a research report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price for the company. Truist Financial lifted their target price on shares of Fresenius Medical Care from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Monday, January 6th. Finally, Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd.

Fresenius Medical Care Price Performance

Shares of NYSE FMS opened at $24.35 on Wednesday. Fresenius Medical Care has a twelve month low of $17.93 and a twelve month high of $25.25. The firm has a market cap of $14.29 billion, a P/E ratio of 20.12, a PEG ratio of 0.82 and a beta of 0.93. The company has a 50 day moving average of $23.36 and a 200 day moving average of $21.34. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.42 by $0.03. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. The company had revenue of $5.23 billion during the quarter, compared to analyst estimates of $5.36 billion. During the same period in the previous year, the business earned $0.31 EPS. As a group, research analysts expect that Fresenius Medical Care will post 1.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Fresenius Medical Care

Hedge funds have recently modified their holdings of the business. Smartleaf Asset Management LLC grew its position in shares of Fresenius Medical Care by 192.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after acquiring an additional 806 shares during the period. Allworth Financial LP lifted its stake in shares of Fresenius Medical Care by 53.1% during the 3rd quarter. Allworth Financial LP now owns 1,675 shares of the company’s stock valued at $36,000 after buying an additional 581 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new position in shares of Fresenius Medical Care during the 3rd quarter valued at $38,000. Jones Financial Companies Lllp lifted its stake in shares of Fresenius Medical Care by 80.5% during the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock valued at $102,000 after buying an additional 2,012 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of Fresenius Medical Care by 50.4% during the 3rd quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock valued at $106,000 after buying an additional 1,675 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.